FESTUCCIA, Claudio
 Distribuzione geografica
Continente #
NA - Nord America 3.450
EU - Europa 2.051
AS - Asia 1.803
SA - Sud America 294
AF - Africa 40
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 5
Totale 7.649
Nazione #
US - Stati Uniti d'America 3.384
SG - Singapore 790
RU - Federazione Russa 526
IE - Irlanda 425
CN - Cina 384
DE - Germania 309
BR - Brasile 259
HK - Hong Kong 204
IT - Italia 188
VN - Vietnam 176
SE - Svezia 161
GB - Regno Unito 99
TR - Turchia 97
UA - Ucraina 85
FI - Finlandia 72
FR - Francia 59
IN - India 44
CA - Canada 43
BE - Belgio 33
CZ - Repubblica Ceca 25
JP - Giappone 21
BD - Bangladesh 20
ZA - Sudafrica 20
PL - Polonia 16
ES - Italia 15
MX - Messico 13
NL - Olanda 12
AR - Argentina 11
IQ - Iraq 10
PK - Pakistan 9
MA - Marocco 8
EC - Ecuador 7
LT - Lituania 7
KR - Corea 6
EU - Europa 5
KZ - Kazakistan 5
AE - Emirati Arabi Uniti 4
UY - Uruguay 4
UZ - Uzbekistan 4
VE - Venezuela 4
AU - Australia 3
CH - Svizzera 3
CL - Cile 3
CO - Colombia 3
DZ - Algeria 3
ID - Indonesia 3
LV - Lettonia 3
PH - Filippine 3
TW - Taiwan 3
AL - Albania 2
AT - Austria 2
BG - Bulgaria 2
BH - Bahrain 2
GY - Guiana 2
HN - Honduras 2
IL - Israele 2
JM - Giamaica 2
JO - Giordania 2
KG - Kirghizistan 2
MY - Malesia 2
NG - Nigeria 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PA - Panama 2
PS - Palestinian Territory 2
RO - Romania 2
TN - Tunisia 2
BN - Brunei Darussalam 1
DO - Repubblica Dominicana 1
EG - Egitto 1
ET - Etiopia 1
GE - Georgia 1
GT - Guatemala 1
HR - Croazia 1
HU - Ungheria 1
KE - Kenya 1
LB - Libano 1
LU - Lussemburgo 1
LY - Libia 1
NO - Norvegia 1
OM - Oman 1
PE - Perù 1
PG - Papua Nuova Guinea 1
QA - Qatar 1
SA - Arabia Saudita 1
SI - Slovenia 1
SN - Senegal 1
TJ - Tagikistan 1
TL - Timor Orientale 1
Totale 7.649
Città #
Dallas 473
Chandler 453
Singapore 450
Dublin 421
Jacksonville 320
San Jose 319
Ashburn 252
Hong Kong 197
Santa Clara 135
New York 104
Ann Arbor 103
Boardman 92
Munich 92
The Dalles 78
Beijing 76
Moscow 67
Izmir 60
L'aquila 58
Nanjing 57
Wilmington 57
Bremen 53
Lawrence 53
Princeton 53
Los Angeles 52
Ho Chi Minh City 51
Hanoi 41
Grafing 38
Woodbridge 38
Brussels 32
Council Bluffs 27
San Mateo 27
Columbus 26
Shenyang 24
Seattle 23
Brno 22
Helsinki 22
Orem 22
Nanchang 21
Lauterbourg 20
São Paulo 20
Turku 19
Tokyo 18
Chennai 16
Falls Church 15
Frankfurt am Main 15
Johannesburg 15
Lappeenranta 15
Montreal 15
Rome 15
Stockholm 15
Kunming 14
Tianjin 14
Warsaw 14
Houston 13
L’Aquila 13
Berlin 12
Brooklyn 12
Dong Ket 12
Milan 12
Toronto 11
Dearborn 10
Falkenstein 10
London 10
Mountain View 10
Amsterdam 9
Atlanta 9
Belo Horizonte 9
Changsha 9
Da Nang 9
Des Moines 9
Haiphong 9
Manchester 9
Phoenix 9
Shanghai 9
Washington 9
Chicago 8
Denver 8
Hebei 8
Jinan 8
Norwalk 8
Poplar 8
San Francisco 8
Ankara 7
Boston 7
Mumbai 7
Pune 7
Hanover 6
Hefei 6
Jiaxing 6
Mexico City 6
Napoli 6
Seoul 6
Baghdad 5
Biên Hòa 5
Curitiba 5
Dhaka 5
Francavilla al Mare 5
Rio de Janeiro 5
Verona 5
Zhengzhou 5
Totale 5.113
Nome #
The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma 201
C-Myc Sustains Transformed Phenotype and Promotes Radioresistance of Embryonal Rhabdomyosarcoma Cell Lines 192
Crocetin and crocin from saffron in cancer chemotherapy and chemoprevention 186
From glioblastoma to endothelial cells through extracellular vesicles: messages for angiogenesis 182
Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells 165
Prevention of chemotherapy-induced gonadotoxicity in the mouse model: protective effects of natural bioactive compounds 159
The Botanical Drug PBI-05204, a Supercritical CO2 Extract of Nerium Oleander, Is Synergistic With Radiotherapy in Models of Human Glioblastoma 157
PPARγ-dependent effects of conjugated linoleic acid on a human glioblastoma cell line (ADF) 156
The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma 156
Clinically relevant radioresistant rhabdomyosarcoma cell lines: Functional, molecular and immune-related characterization 154
Crocetin extracted from saffron shows antitumor effects in models of human glioblastoma 154
EPHRIN A2 ANTAGONISM REDUCES SURVIVAL OF PROSTATE CANCR CELLS AFTER CHEMOTHERAPIC TREATMENTS AND ANGIOGENESIS IN PROSTATE CANCER CELLS BOTH IN VITRO AND IN VIVO 150
Increased expression and activity of p75NTR are crucial events in azacitidine-induced cell death in prostate cancer 149
Immunolocalization of Advanced Glycation End Products, Mitogen Activated Protein Kinases, and Transforming Growth Factor-β/Smads in Pelvic Organ Prolapse 149
Tebuconazole and Econazole Act Synergistically in Mediating Mitochondrial Stress, Energy Imbalance, and Sequential Activation of Autophagy and Apoptosis in Mouse Sertoli TM4 Cells: Possible Role of AMPK/ULK1 Axis 149
Lactobacillus sakei pro-bio65 reduces tnf-α expression and upregulates gsh content and antioxidant enzymatic activities in human conjunctival cells 146
CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models 145
Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgenindependent prostate cancer cells to DNA damage 145
Antitumorigenic Effects of Inhibiting Ephrin Receptor Kinase Signaling by GLPG1790 against Colorectal Cancer Cell Lines in Vitro and in Vivo 145
The brain penetrating and dual TORC1/TORC2 inhibitor, RES529, elicits anti-glioma activity and enhances the therapeutic effects of anti-angiogenetic compounds in preclinical murine models 144
HDAC4 and HDAC6 sustain DNA double strand break repair and stem-like phenotype by promoting radioresistance in glioblastoma cells 143
Synergistic Activity of Ketoconazole and Miconazole with Prochloraz in Inducing Oxidative Stress, GSH Depletion, Mitochondrial Dysfunction, and Apoptosis in Mouse Sertoli TM4 Cells 141
ATX-101, a Peptide Targeting PCNA, Has Antitumor Efficacy Alone or in Combination with Radiotherapy in Murine Models of Human Glioblastoma 140
Multiple Antitumor Molecular Mechanisms Are Activated by a Fully Synthetic and Stabilized Pharmaceutical Product Delivering the Active Compound Sulforaphane (SFX-01) in Preclinical Model of Human Glioblastoma 139
The Small Molecule Ephrin Receptor Inhibitor, GLPG1790, Reduces Renewal Capabilities of Cancer Stem Cells, Showing Anti-Tumour Efficacy on Preclinical Glioblastoma Models 136
Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous Growth 136
Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models 136
Suppression of SRC signaling is effective in reducing synergy between glioblastoma and stromal cells 135
Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo 134
Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer 133
Correction: The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma (Journal of Hematology and Oncology (2018) 11(32) DOI: 10.1186/s13045-018-0576-6) 130
Can the AGE/RAGE/ERK signalling pathway and the epithelial-to-mesenchymal transition interact in the pathogenesis of chronic rhinosinusitis with nasal polyps? 130
UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice 129
Pro-differentiating and radiosensitizing effects of inhibiting HDACs by PXD-101 (Belinostat) in in vitro and in vivo models of human rhabdomyosarcoma cell lines 128
Romidepsin (FK228) fails in counteracting the transformed phenotype of rhabdomyosarcoma cells but efficiently radiosensitizes, in vitro and in vivo, the alveolar phenotype subtype 125
KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and surviving in prostate cancer models 124
Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma 124
Correction to: Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma (Journal of Cancer Research and Clinical Oncology, (2019), 145, 2, (393-409), 10.1007/s00432-018-2800-8) 124
Ms−275 (Entinostat) promotes radio-sensitivity in pax3-foxo1 rhabdomyosarcoma cells 124
Episode-like pulse testosterone supplementation induces tumor senescence and growth arrest down-modulating androgen receptor through modulation of p-ERK1/2, pARser81 and CDK1 signaling: biological implications for men treated with testosterone replacement therapy 123
Sulodexide counteracts endothelial dysfunction induced by metabolic or non-metabolic stresses through activation of the autophagic program 122
Vitamin D protects endothelial cells from irradiation-induced senescence and apoptosis by modulating MAPK/SirT1 axis 120
Editorial: Antitarget Therapies: New Frontiers in the Treatment of Cancer 118
The importance of tumor stem cells in glioblastoma resistance to therapy 118
Dual PI3 K/mTOR inhibition reduces prostate cancer bone engraftment altering tumor-induced bone remodeling 114
The possible prognostic role of histone deacetylase and transforming growth factor β/Smad signaling in high grade gliomas treated by radio-chemotherapy: a preliminary immunohistochemical study 112
Targeting ddx3x helicase activity with ba103 shows promising therapeutic effects in preclinical glioblastoma models 112
Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models 110
Fertility preservation in cancer patients: attenuation of chemotherapy-induced ovarian damage by oral administration of phytochemical carotenoids in an animal model. 109
The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models 105
Editorial: New Drug Targets for Treatment of Recurrent/Metastatic Prostate Cancer 97
The Botanical Drug PBI-05204, a Supercritical CO2 Extract of Nerium Oleander, Inhibits Growth of Human Glioblastoma, Reduces Akt/mTOR Activities, and Modulates GSC Cell-Renewal Properties 97
Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer models. 94
Prodrugs of Pyrazolo[3,4-d]pyrimidines: From Library Synthesis to Evaluation as Potential Anticancer Agents in an Orthotopic Glioblastoma Model 92
The botanical drug PBI-05204, a supercritical CO2 extract of Nerium oleander, sensitizes alveolar and embryonal rhabdomyosarcoma to radiotherapy in vitro and in vivo 88
New therapeutic approaches for the treatmemt of glioblastoma 85
Antitumour effects of SFX-01 molecule in combination with ionizing radiation in preclinical and in vivo models of rhabdomyosarcoma 78
General Direct Anticancer Effects of Deer Growing Antler Extract in Several Tumour Cell Lines, and Immune System-Mediated Effects in Xenograft Glioblastoma 70
A Pharmacological Investigation of Eph-Ephrin Antagonism in Prostate Cancer: UniPR1331 Efficacy Evidence 67
Targeted molecular therapy in glioblastoma 51
Totale 7.777
Categoria #
all - tutte 29.323
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.323


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021124 0 0 0 0 0 0 0 0 0 23 71 30
2021/2022399 22 3 68 25 12 54 16 14 35 37 25 88
2022/20231.236 73 93 18 173 105 120 0 92 502 11 30 19
2023/2024351 42 13 20 13 26 135 10 12 1 9 17 53
2024/20251.503 39 31 98 104 169 126 214 126 280 103 130 83
2025/20262.938 154 281 391 418 319 178 419 94 246 438 0 0
Totale 7.777